Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1012130

	registered interest
	date	21/11/2018
	answering body	Foreign and Commonwealth Office
	answering dept id	16
	answering dept short name	Foreign and Commonwealth Office
	answering dept sort name	Foreign and Commonwealth Office
	hansard heading	Gaza: Israel
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what action they are taking to support the ceasefire in Gaza agreed on 13 November.
	tabling member printed	The Marquess of Lothian
	uin	HL11657
	answer	answer is ministerial correction date of answer 05/12/2018 answer text <p>​We urge restraint from all parties and welcome the return to calm in recent days. We strongly support the mediation efforts of the international community led by Egypt and the UN and urge continued talks aimed at finding an enduring peace in Gaza. In order to protect civilians it is crucial that a ceasefire is agreed and maintained as part of a political process that sees the Palestinian Authority return to Gaza, and that restrictions on the Gazan people and economy are lifted.</p> answering member printed Lord Ahmad of Wimbledon question first answered 05/12/2018 12:27:45 answering member 4210 label Biography information for Lord Ahmad of Wimbledon
	tabling member	259 label Biography information for The Marquess of Lothian

1012155

	registered interest
	date	21/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what arrangements they have put in place so far to ensure that NHS patients have access to a supply of (1) medicines, (2) vaccines, and (3) medical devices that their healthcare requires after 29 March 2019 if no Brexit withdrawal deal is agreed.
	tabling member printed	Lord Warner
	uin	HL11682
	answer	answer is ministerial correction date of answer 05/12/2018 answer text <p>As the Government has now agreed, in principle, the Withdrawal Agreement with the European Commission, the Department has assessed that market access to medicines and medical equipment under the terms of that agreement will remain unchanged for industry and</p><p>the National Health Service during the implementation period, which will run from March 2019 until December 2020.</p><p>As a responsible Government, however, we continue to prepare proportionately for all scenarios, including the unlikely outcome that we leave the European Union without any deal in March 2019.</p><p>The Department has held confidential discussions with logistics companies and trade associations representing the vast majority of the medical suppliers in developing its plans.</p><p>On 23 August 2018, the Department wrote to pharmaceutical companies that supply the United Kingdom with selected pharmacy or prescription-only medicines, including non-national programme vaccines, from, or via, the EU/European Economic Area, asking them to ensure they have a minimum of six weeks’ additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the event of a no deal EU exit. On the same date, the Government published two technical notices on the batch testing and regulation of human medicines in the event of a no deal, together with a further technical notice on the submission of regulatory information on medical products.</p><p>Officials in Public Health England are leading a programme to ensure the continuity of supply for all centrally procured vaccines which are distributed to the NHS for the UK National Immunisation Programme.</p><p>On 23 August, the Department also announced contingency measures to increase stock holding at a national level for medical devices and clinical consumables. To this end, we are working with suppliers that routinely import products from EU countries to determine what measures they need to take so that they can continue to provide products in the unlikely event of a no deal EU exit.</p><p>Since these initiatives were announced, the Department has received very good engagement from industry who share our aims of ensuring continuity of medical supplies for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal EU exit.</p><p>On 23 August, the Department also wrote to all NHS trusts, pharmacies, healthcare providers and general practices to inform them of our contingency plans for ensuring continuity of supply of medical supplies. The NHS was asked not to stockpile medicines and clinicians were advised to tell patients that the Government has plans in place to ensure a continued supply and they will not need to and should not seek to store extra supply at home.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL11683 HL11684 HL11685 HL11686 HL11687 question first answered 05/12/2018 12:26:19 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1732 label Biography information for Lord Warner

1012156

	registered interest
	date	21/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what discussions they are having with the suppliers of (1) medicines, (2) vaccines, and (3) medical devices about the access of NHS patients to their products after 29 March 2019 if no Brexit deal is agreed.
	tabling member printed	Lord Warner
	uin	HL11683
	answer	answer is ministerial correction date of answer 05/12/2018 answer text <p>As the Government has now agreed, in principle, the Withdrawal Agreement with the European Commission, the Department has assessed that market access to medicines and medical equipment under the terms of that agreement will remain unchanged for industry and</p><p>the National Health Service during the implementation period, which will run from March 2019 until December 2020.</p><p>As a responsible Government, however, we continue to prepare proportionately for all scenarios, including the unlikely outcome that we leave the European Union without any deal in March 2019.</p><p>The Department has held confidential discussions with logistics companies and trade associations representing the vast majority of the medical suppliers in developing its plans.</p><p>On 23 August 2018, the Department wrote to pharmaceutical companies that supply the United Kingdom with selected pharmacy or prescription-only medicines, including non-national programme vaccines, from, or via, the EU/European Economic Area, asking them to ensure they have a minimum of six weeks’ additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the event of a no deal EU exit. On the same date, the Government published two technical notices on the batch testing and regulation of human medicines in the event of a no deal, together with a further technical notice on the submission of regulatory information on medical products.</p><p>Officials in Public Health England are leading a programme to ensure the continuity of supply for all centrally procured vaccines which are distributed to the NHS for the UK National Immunisation Programme.</p><p>On 23 August, the Department also announced contingency measures to increase stock holding at a national level for medical devices and clinical consumables. To this end, we are working with suppliers that routinely import products from EU countries to determine what measures they need to take so that they can continue to provide products in the unlikely event of a no deal EU exit.</p><p>Since these initiatives were announced, the Department has received very good engagement from industry who share our aims of ensuring continuity of medical supplies for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal EU exit.</p><p>On 23 August, the Department also wrote to all NHS trusts, pharmacies, healthcare providers and general practices to inform them of our contingency plans for ensuring continuity of supply of medical supplies. The NHS was asked not to stockpile medicines and clinicians were advised to tell patients that the Government has plans in place to ensure a continued supply and they will not need to and should not seek to store extra supply at home.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL11682 HL11684 HL11685 HL11686 HL11687 question first answered 05/12/2018 12:26:19 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1732 label Biography information for Lord Warner

1012157

	registered interest
	date	21/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what discussions they are having with product transport and product supplier bodies about safeguarding to NHS patients after 29 March 2019 the supply of (1) medicines, (2) vaccines, and (3) medical devices if no Brexit withdrawal deal is agreed; and what conclusions these discussions have reached.
	tabling member printed	Lord Warner
	uin	HL11684
	answer	answer is ministerial correction date of answer 05/12/2018 answer text <p>As the Government has now agreed, in principle, the Withdrawal Agreement with the European Commission, the Department has assessed that market access to medicines and medical equipment under the terms of that agreement will remain unchanged for industry and</p><p>the National Health Service during the implementation period, which will run from March 2019 until December 2020.</p><p>As a responsible Government, however, we continue to prepare proportionately for all scenarios, including the unlikely outcome that we leave the European Union without any deal in March 2019.</p><p>The Department has held confidential discussions with logistics companies and trade associations representing the vast majority of the medical suppliers in developing its plans.</p><p>On 23 August 2018, the Department wrote to pharmaceutical companies that supply the United Kingdom with selected pharmacy or prescription-only medicines, including non-national programme vaccines, from, or via, the EU/European Economic Area, asking them to ensure they have a minimum of six weeks’ additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the event of a no deal EU exit. On the same date, the Government published two technical notices on the batch testing and regulation of human medicines in the event of a no deal, together with a further technical notice on the submission of regulatory information on medical products.</p><p>Officials in Public Health England are leading a programme to ensure the continuity of supply for all centrally procured vaccines which are distributed to the NHS for the UK National Immunisation Programme.</p><p>On 23 August, the Department also announced contingency measures to increase stock holding at a national level for medical devices and clinical consumables. To this end, we are working with suppliers that routinely import products from EU countries to determine what measures they need to take so that they can continue to provide products in the unlikely event of a no deal EU exit.</p><p>Since these initiatives were announced, the Department has received very good engagement from industry who share our aims of ensuring continuity of medical supplies for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal EU exit.</p><p>On 23 August, the Department also wrote to all NHS trusts, pharmacies, healthcare providers and general practices to inform them of our contingency plans for ensuring continuity of supply of medical supplies. The NHS was asked not to stockpile medicines and clinicians were advised to tell patients that the Government has plans in place to ensure a continued supply and they will not need to and should not seek to store extra supply at home.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL11682 HL11683 HL11685 HL11686 HL11687 question first answered 05/12/2018 12:26:19 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1732 label Biography information for Lord Warner

1012158

	registered interest
	date	21/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what guidance they have given to (1) NHS England, (2) the wider NHS, and (3) suppliers, on the stockpiling of (a) medicines, (b) vaccines, and (c) medical devices in order to safeguard the healthcare of NHS patients after 29 March 2019 if no Brexit withdrawal deal is agreed.
	tabling member printed	Lord Warner
	uin	HL11685
	answer	answer is ministerial correction date of answer 05/12/2018 answer text <p>As the Government has now agreed, in principle, the Withdrawal Agreement with the European Commission, the Department has assessed that market access to medicines and medical equipment under the terms of that agreement will remain unchanged for industry and</p><p>the National Health Service during the implementation period, which will run from March 2019 until December 2020.</p><p>As a responsible Government, however, we continue to prepare proportionately for all scenarios, including the unlikely outcome that we leave the European Union without any deal in March 2019.</p><p>The Department has held confidential discussions with logistics companies and trade associations representing the vast majority of the medical suppliers in developing its plans.</p><p>On 23 August 2018, the Department wrote to pharmaceutical companies that supply the United Kingdom with selected pharmacy or prescription-only medicines, including non-national programme vaccines, from, or via, the EU/European Economic Area, asking them to ensure they have a minimum of six weeks’ additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the event of a no deal EU exit. On the same date, the Government published two technical notices on the batch testing and regulation of human medicines in the event of a no deal, together with a further technical notice on the submission of regulatory information on medical products.</p><p>Officials in Public Health England are leading a programme to ensure the continuity of supply for all centrally procured vaccines which are distributed to the NHS for the UK National Immunisation Programme.</p><p>On 23 August, the Department also announced contingency measures to increase stock holding at a national level for medical devices and clinical consumables. To this end, we are working with suppliers that routinely import products from EU countries to determine what measures they need to take so that they can continue to provide products in the unlikely event of a no deal EU exit.</p><p>Since these initiatives were announced, the Department has received very good engagement from industry who share our aims of ensuring continuity of medical supplies for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal EU exit.</p><p>On 23 August, the Department also wrote to all NHS trusts, pharmacies, healthcare providers and general practices to inform them of our contingency plans for ensuring continuity of supply of medical supplies. The NHS was asked not to stockpile medicines and clinicians were advised to tell patients that the Government has plans in place to ensure a continued supply and they will not need to and should not seek to store extra supply at home.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL11682 HL11683 HL11684 HL11686 HL11687 question first answered 05/12/2018 12:26:19 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1732 label Biography information for Lord Warner

1012159

	registered interest
	date	21/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what guidance will be given to doctors and patients about obtaining and storing supplies of medicines if no Brexit withdrawal deal is agreed.
	tabling member printed	Lord Warner
	uin	HL11686
	answer	answer is ministerial correction date of answer 05/12/2018 answer text <p>As the Government has now agreed, in principle, the Withdrawal Agreement with the European Commission, the Department has assessed that market access to medicines and medical equipment under the terms of that agreement will remain unchanged for industry and</p><p>the National Health Service during the implementation period, which will run from March 2019 until December 2020.</p><p>As a responsible Government, however, we continue to prepare proportionately for all scenarios, including the unlikely outcome that we leave the European Union without any deal in March 2019.</p><p>The Department has held confidential discussions with logistics companies and trade associations representing the vast majority of the medical suppliers in developing its plans.</p><p>On 23 August 2018, the Department wrote to pharmaceutical companies that supply the United Kingdom with selected pharmacy or prescription-only medicines, including non-national programme vaccines, from, or via, the EU/European Economic Area, asking them to ensure they have a minimum of six weeks’ additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the event of a no deal EU exit. On the same date, the Government published two technical notices on the batch testing and regulation of human medicines in the event of a no deal, together with a further technical notice on the submission of regulatory information on medical products.</p><p>Officials in Public Health England are leading a programme to ensure the continuity of supply for all centrally procured vaccines which are distributed to the NHS for the UK National Immunisation Programme.</p><p>On 23 August, the Department also announced contingency measures to increase stock holding at a national level for medical devices and clinical consumables. To this end, we are working with suppliers that routinely import products from EU countries to determine what measures they need to take so that they can continue to provide products in the unlikely event of a no deal EU exit.</p><p>Since these initiatives were announced, the Department has received very good engagement from industry who share our aims of ensuring continuity of medical supplies for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal EU exit.</p><p>On 23 August, the Department also wrote to all NHS trusts, pharmacies, healthcare providers and general practices to inform them of our contingency plans for ensuring continuity of supply of medical supplies. The NHS was asked not to stockpile medicines and clinicians were advised to tell patients that the Government has plans in place to ensure a continued supply and they will not need to and should not seek to store extra supply at home.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL11682 HL11683 HL11684 HL11685 HL11687 question first answered 05/12/2018 12:26:19 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1732 label Biography information for Lord Warner

1012160

	registered interest
	date	21/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what arrangements they will put in place to ensure the provision of medicines and medical supplies to acute hospitals after 29 March 2019 if no Brexit withdrawal deal is agreed.
	tabling member printed	Lord Warner
	uin	HL11687
	answer	answer is ministerial correction date of answer 05/12/2018 answer text <p>As the Government has now agreed, in principle, the Withdrawal Agreement with the European Commission, the Department has assessed that market access to medicines and medical equipment under the terms of that agreement will remain unchanged for industry and</p><p>the National Health Service during the implementation period, which will run from March 2019 until December 2020.</p><p>As a responsible Government, however, we continue to prepare proportionately for all scenarios, including the unlikely outcome that we leave the European Union without any deal in March 2019.</p><p>The Department has held confidential discussions with logistics companies and trade associations representing the vast majority of the medical suppliers in developing its plans.</p><p>On 23 August 2018, the Department wrote to pharmaceutical companies that supply the United Kingdom with selected pharmacy or prescription-only medicines, including non-national programme vaccines, from, or via, the EU/European Economic Area, asking them to ensure they have a minimum of six weeks’ additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the event of a no deal EU exit. On the same date, the Government published two technical notices on the batch testing and regulation of human medicines in the event of a no deal, together with a further technical notice on the submission of regulatory information on medical products.</p><p>Officials in Public Health England are leading a programme to ensure the continuity of supply for all centrally procured vaccines which are distributed to the NHS for the UK National Immunisation Programme.</p><p>On 23 August, the Department also announced contingency measures to increase stock holding at a national level for medical devices and clinical consumables. To this end, we are working with suppliers that routinely import products from EU countries to determine what measures they need to take so that they can continue to provide products in the unlikely event of a no deal EU exit.</p><p>Since these initiatives were announced, the Department has received very good engagement from industry who share our aims of ensuring continuity of medical supplies for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal EU exit.</p><p>On 23 August, the Department also wrote to all NHS trusts, pharmacies, healthcare providers and general practices to inform them of our contingency plans for ensuring continuity of supply of medical supplies. The NHS was asked not to stockpile medicines and clinicians were advised to tell patients that the Government has plans in place to ensure a continued supply and they will not need to and should not seek to store extra supply at home.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL11682 HL11683 HL11684 HL11685 HL11686 question first answered 05/12/2018 12:26:19 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1732 label Biography information for Lord Warner

1013193

	registered interest
	date	23/11/2018
	answering body	Department for Education
	answering dept id	60
	answering dept short name	Education
	answering dept sort name	Education
	hansard heading	Apprentices
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what percentage of those undertaking apprenticeships are from isolated communities, as defined in the Integrated Communities Strategy green paper, published on 14 March.
	tabling member printed	Lord Murphy of Torfaen
	uin	HL11753
	answer	answer is ministerial correction date of answer 05/12/2018 answer text <p>A definition for ‘isolated communities’ is not available in the Communities Strategy green paper, and as such a percentage of apprenticeship starts for this cohort cannot be provided. However, The Ministry of Housing, Communities and Local Government has set an action which builds on the proposal set out in March’s green paper to “use targeted local communications and community ambassadors, including employers, to ensure minority ethnic groups are applying, getting and completing apprenticeships, and that local employers are recruiting apprentices.” The government will respond to the consultation on the Integrated Communities Strategy green paper later this year.</p><p>The department does publish apprenticeship data on under-represented groups, and we have provided apprenticeship starts by a breakdown of detailed ethnicity to provide an alternative categorisation of cohorts which may fall under the ‘isolated communities’ definition. The table below provides apprenticeship starts broken down by detailed ethnicity from August 2017 to April 2018 as first reported for the 2017/18 academic year:</p><table><tbody><tr><td><p><strong>Detailed Ethnicity</strong></p></td><td><p><strong>Starts</strong></p></td><td><p><strong>Percentage of total</strong></p></td></tr><tr><td><p>African</p></td><td><p>4,530</p></td><td><p><em>1.6%</em></p></td></tr><tr><td><p>Any other Asian Background</p></td><td><p>2,830</p></td><td><p><em>1.0%</em></p></td></tr><tr><td><p>Any other Black/African/Caribbean Background</p></td><td><p>1,760</p></td><td><p><em>0.6%</em></p></td></tr><tr><td><p>Any other ethnic group</p></td><td><p>2,000</p></td><td><p><em>0.7%</em></p></td></tr><tr><td><p>Any other Mixed / multiple ethnic background</p></td><td><p>2,020</p></td><td><p><em>0.7%</em></p></td></tr><tr><td><p>Any Other White Background</p></td><td><p>12,850</p></td><td><p><em>4.4%</em></p></td></tr><tr><td><p>Arab</p></td><td><p>320</p></td><td><p><em>*</em></p></td></tr><tr><td><p>Bangladeshi</p></td><td><p>1,930</p></td><td><p><em>0.7%</em></p></td></tr><tr><td><p>Caribbean</p></td><td><p>2,760</p></td><td><p><em>1.0%</em></p></td></tr><tr><td><p>Chinese</p></td><td><p>440</p></td><td><p><em>*</em></p></td></tr><tr><td><p>English / Welsh / Scottish / Northern Irish / British</p></td><td><p>239,480</p></td><td><p><em>82.4%</em></p></td></tr><tr><td><p>Gypsy or Irish Traveller</p></td><td><p>130</p></td><td><p><em>*</em></p></td></tr><tr><td><p>Indian</p></td><td><p>4,000</p></td><td><p><em>1.4%</em></p></td></tr><tr><td><p>Irish</p></td><td><p>1,090</p></td><td><p><em>*</em></p></td></tr><tr><td><p>Not Provided</p></td><td><p>5,070</p></td><td><p><em>1.7%</em></p></td></tr><tr><td><p>Pakistani</p></td><td><p>4,080</p></td><td><p><em>1.4%</em></p></td></tr><tr><td><p>White and Asian</p></td><td><p>1,430</p></td><td><p><em>0.5%</em></p></td></tr><tr><td><p>White and Black African</p></td><td><p>900</p></td><td><p><em>*</em></p></td></tr><tr><td><p>White and Black Caribbean</p></td><td><p>2,870</p></td><td><p><em>1.0%</em></p></td></tr><tr><td><p><strong>Totals</strong></p></td><td><p><strong> 290,470 </strong></p></td><td><p><strong><em>100.0%</em></strong></p></td></tr></tbody></table><p>1) Volumes are rounded to the nearest ten, whilst ‘*’ indicates a percentage of less that 0.5.</p><p>2) The data source is the Individualised Learner Record (ILR).</p><p>These figures are published and are available in the further education data library: <a href="https://www.gov.uk/government/collections/fe-data-library" target="_blank">https://www.gov.uk/government/collections/fe-data-library</a>.</p> answering member printed Lord Agnew of Oulton question first answered 05/12/2018 12:22:05 answering member 4689 label Biography information for Lord Agnew of Oulton
	tabling member	546 label Biography information for Lord Murphy of Torfaen

1013197

	registered interest
	date	23/11/2018
	answering body	Department for Education
	answering dept id	60
	answering dept short name	Education
	answering dept sort name	Education
	hansard heading	Vocational Guidance
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what progress they have made on the Careers Strategy pilot scheme for routes into careers for vulnerable groups.
	tabling member printed	Lord Murphy of Torfaen
	uin	HL11757
	answer	answer is ministerial correction date of answer 05/12/2018 answer text <p>To target more support on those who need it most, the government has invested £5 million during 2018 in a new round of the Careers &amp; Enterprise Company’s funding. This will help disadvantaged pupils to receive the additional support that they need to prepare for work, including opportunities for mentoring and personal guidance from a qualified careers professional. We have also established 20 Careers Hubs focused on groups of young people and areas most in need of targeted support and we have announced a further 20 Careers Hubs for 2019.</p><p>The government is also providing funding of £1.7 million to test new approaches and produce resources to improve careers information, advice and guidance for individuals who are disadvantaged or vulnerable. We want to broaden aspirations and raise awareness of pathways into training and work for young people with special educational needs and disabilities; looked after children and care leavers; and young people from Gypsy, Roma and Traveller communities. Organisations have been recruited and work with these groups will start in January 2019.</p><p> </p> answering member printed Lord Agnew of Oulton question first answered 05/12/2018 12:27:19 answering member 4689 label Biography information for Lord Agnew of Oulton
	tabling member	546 label Biography information for Lord Murphy of Torfaen

1015877

	registered interest
	date	27/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what advice the Secretary of State for Health and Social Care receives when deciding how to instruct NICE in relation to whether to use the Single Technology Appraisal route or the Highly Specialised Technology route when assessing a new medicine or treatment.
	tabling member printed	Baroness Walmsley
	uin	HL11871
	answer	answer is ministerial correction date of answer 05/12/2018 answer text <p>Departmental Ministers, on behalf of the Secretary of State, take decisions on the final referral of topics to the National Institute for Health and Care Excellence (NICE) technology appraisal and highly specialised technology work programmes on the basis of advice from the Department’s officials. The advice summarises the outcome of a topic selection process that is overseen by NICE and includes consideration of topics against published criteria by a group comprising representatives from the Department, NHS England and NICE and informed by public consultation.</p> answering member printed Lord O'Shaughnessy question first answered 05/12/2018 12:22:41 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2547 label Biography information for Baroness Walmsley